A practical approach for bridging anticoagulation after mechanical heart valve replacement

Journal of Heart Valve Disease

Volumn 17, Issue 3, 2008, Pages 335-342

  Steger, Volker ^a   Bail, Dorothee H ^b   Graf, Daniela ^a   Walker, Tobias ^b   Rittig, Kilian ^b   Ziemer, Gerhard ^b  

^a Schillerhöhe Hospital   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; VITAMIN K GROUP;

AGED; AORTA VALVE; ARTICLE; CARDIOVASCULAR SURGERY; DOSE RESPONSE; DRUG ANTAGONISM; FEMALE; HEART VALVE PROSTHESIS; HUMAN; MALE; MITRAL VALVE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; POSTOPERATIVE CARE; RETROSPECTIVE STUDY; THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; AORTIC VALVE; CARDIOVASCULAR SURGICAL PROCEDURES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FEMALE; HEART VALVE PROSTHESIS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MITRAL VALVE; OUTCOME ASSESSMENT (HEALTH CARE); POSTOPERATIVE CARE; RETROSPECTIVE STUDIES; THROMBOEMBOLISM; VITAMIN K;

EID: 53449087754     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-17
2. Gohlke-Barwolf C, Acar J, Oakley C, et al. (Recommendations for prevention of thromboembolism in heart valve diseases. Working Group on Valvular Heart Disease, European Society of Cardiology). Z Kardiol 1995;84:1018-1032
3. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of deep vein thrombosis after major knee surgery: A randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992;67:417-423
4. Turpie AG, Levine MN, Hirsh J, et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986;315:925-929 (Pubitemid 16023679)
5. Colwell CW, Jr., Spiro TE, Trowbridge AA, et al. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. Clin Orthop Relat Res 1995;321:19-27
6. Colwell CW, Jr., Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 1994;76:3-14 (Pubitemid 24081799)
7. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447-452 (Pubitemid 27333045)
8. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601 (Pubitemid 29477267)
9. Montalescot G, Polle V, Collet JP, et al. Low molecular weight heparin after mechanical heart valve replacement. Circulation 2000;101:1083-1086 (Pubitemid 30146606)
10. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecularweight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004;110:1658-1663 (Pubitemid 39297990)
11. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: Assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004;164:1319-1326 (Pubitemid 38828883)
12. Fanikos J, Tsilimingras K, Kucher N, et al. Comparison of efficacy, safety, and cost of lowmolecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. Am J Cardiol 2004;93:247-250 (Pubitemid 38058745)
13. Meurin P, Tabet JY, Weber H, et al. Low-molecularweight heparin as a bridging anticoagulant early after mechanical heart valve replacement. Circulation 2006;113:564-569
14. Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000;26(Suppl.1):31-38
15. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995;73:630-640
16. Eriksson BI, Soderberg K, Widlund L, et al. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995;73:398-401
17. Frydman A. Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 1996;26(Suppl.2):24-38 (Pubitemid 26099958)
18. Bara L, Bloch MF, Zitoun D, et al. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res 1993;69:443-452 (Pubitemid 23102564)
19. Buckley MM, Sorkin EM. Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992;44:465-497
20. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470 (Pubitemid 29135798)
21. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: A systematic review. Arch Intern Med 2003;163:901-908 (Pubitemid 36522737)
22. Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993;119:104-109 (Pubitemid 23286474)
23. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993;329:673-682
24. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-681 (Pubitemid 26079800)
25. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol 2000;36:693-698
26. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94S (Pubitemid 32154195)
27. Samama MM, Poller L. Contemporary laboratory monitoring of low molecular weight heparins. Clin Lab Med 1995;15:119-123
28. Seshadri N, Goldhaber SZ, Elkayam U, et al. The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: An evidencebased comparative review focusing on anticoagulation options in pregnant and nonpregnant patients. Am Heart J 2005;150:27-34 (Pubitemid 41097426)
29. Gerlach AT, Pickworth KK, Seth SK, et al. Enoxaparin and bleeding complications: A review in patients with and without renal insufficiency. Pharmacotherapy 2000;20:771-775 (Pubitemid 30457356)
30. Spinier SA, Inverso SM, Cohen M, et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: Analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003;146:33-41 (Pubitemid 36851297)
31. Ageno W, Turpie AG. Exaggerated initial response to warfarin following heart valve replacement. Am J Cardiol 1999;84:905-908 (Pubitemid 29475074)
32. Ferreira I, Dos L, Tomos P, et al. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart 2003;89:527-530 (Pubitemid 36520802)
33. Kovacs MJ, Weir K, MacKinnon K, et al. Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery. Thromb Res 1998;91:137-142 (Pubitemid 28428206)
34. Kruse MW, Lee JJ. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J 2004;148:582-589 (Pubitemid 39349375)